1-EBIO
CFTR potentiator
General information
1-EBIO is an experimental substance used in studies and not yet available as a human pharmaceutical. Based on its characteristics as a calcium channel agonist, it has the potential to combat cardiac failure and endocrinological disorders. In relation to cystic fibrosis, our AIM tool found the data that 1-EBIO can help potentiate mutant CFTR channels that have a residual function.
Synonyms
1-ethyl-2-benzimidazolone
Marketed as
N/A
Dietary sources
N/A
C9H10N2O
Drug-Mutation Relation
Treats
Does not treat
| Mutation | Number of sources | Average impact factor | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
A561E/A561E
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/120del23
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/1525-1 G->A
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/182delT
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/A561E
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/F508del
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/G542X
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/G85E
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/N1303K
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/Q39X
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/Q552X
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/W57X
|
1 | 4.09 | ||||||||
|
||||||||||
|
F508del/Y1092X
|
1 | 4.09 | ||||||||
|
||||||||||
|
G85E/G85E
|
1 | 4.09 | ||||||||
|
||||||||||
|
Q552X/R1162X
|
1 | 4.09 | ||||||||
|
||||||||||
|
R1158X/2183AA->G
|
1 | 4.09 | ||||||||
|
||||||||||
|
R1158X/R560T
|
1 | 4.09 | ||||||||
|
||||||||||
|
R764X/1717-1 G->A
|
1 | 4.09 | ||||||||
|
||||||||||